Clinical Trials

40 enrolled

Carcinoma, Hepatocellular

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05063565 2026-03-27

ROWAN

100 enrolled

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

27 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

58 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04945720 2026-02-25

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Phase 2 Completed

30 enrolled 9 charts

Carcinoma, Hepatocellular

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

39 enrolled

Carcinoma, Hepatocellular

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

32 enrolled

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07081633 2025-12-30

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Carcinoma, Hepatocellular

NCT07226063 2025-11-10

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

16 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06698250 2025-11-06

ZENOBIA

40 enrolled

Carcinoma, Hepatocellular

NCT06999694 2025-09-10

Proton-STRIDE

45 enrolled

Carcinoma, Hepatocellular

NCT05194293 2025-09-04

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

4 enrolled

Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07122089 2025-08-14

IOSPHERE

80 enrolled

Carcinoma, Hepatocellular

NCT07012798 2025-06-10

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06999707 2025-06-05

Photon-STRIDE

45 enrolled

Carcinoma, Hepatocellular

NCT06045975 2025-04-02

DUMELEP

Carcinoma, Hepatocellular

NCT04294498 2025-03-26

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

Carcinoma, Hepatocellular, Hepatitis B, Chronic

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Carcinoma, Hepatocellular

NCT05027425 2024-11-22

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT05440864 2024-10-10

(NEOTOMA)

28 enrolled

Carcinoma, Hepatocellular

NCT05844046 2024-07-16

MONTBLANC

83 enrolled

Carcinoma, Hepatocellular

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

90 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04988945 2023-09-06

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

33 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05809869 2023-04-12

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Phase 2 Completed

54 enrolled 14 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05312216 2023-01-26

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT03482102 2022-09-08

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

70 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04961918 2021-07-14

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

36 enrolled

Carcinoma, Hepatocellular

NCT04913480 2021-06-04

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

37 enrolled